First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab

The CD52-targeting antibody alemtuzumab is established in clinical practice with convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab was tested and finally approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Schweighofer, Carmen Diana, Wendtner, Clemens-Martin
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895774/
https://www.ncbi.nlm.nih.gov/pubmed/20616957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2895774/
https://www.ncbi.nlm.nih.gov/pubmed/20616957

Ejemplares similares